Optimization of [18F]Flurpiridaz PET; a technical and practical feasibility study

Towards imaging protocol optimization for myocardial perfusion imaging with [18F]Flurpiridaz; a technical and practical feasibility study - TOPF-MPI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON61263

Enrollment

Registered

2025-10-15

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected coronary artery disease Suspected coronary artery disease

Interventions

{18F]Flurpiridaz PET/CT

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult =18 years and referred to the Nuclear Medicine Department for a conventional [18F]Flurpiridaz MPI PET/CT

Exclusion criteria

Exclusion criteria: PregnancyExperienced complications during routine pharmacological stress testing

Design outcomes

Primary

Measure	Time frame
Confirmation of maintained scan quality, by qualitative assessment.	—

Secondary

Measure	Time frame
Confirm logistical feasibility of B2B [18F]Flurpiridaz MPI PET/CTValidate quantification of myocardial blood flow, compared to conventional [18F]Flurpiridaz MPI PET/CT	—

Countries

Netherlands

Contacts

Public ContactA.J.A.T. Braat

Universitair Medisch Centrum Utrecht

a.j.a.t.braat@umcutrecht.nl0887558855

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 29, 2026